Get informed when a big investor buys or sells
+ Follow-19.16%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
InflaRx N.V. (IFRX) currently reports a ROE of -19.16%. That is below the Healthcare sector average of 13.26%. Use the charts on this page to explore InflaRx N.V.'s ROE history and peer comparisons.
InflaRx N.V.'s ROE of -19.16% is lower than the Healthcare sector average of 13.26%. That is roughly 244.5% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but InflaRx N.V.'s current -19.16% should be judged against Healthcare norms (sector average: 13.26%) and against IFRX's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of -19.16%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 13.26%. From there, open related valuation or income-statement pages for InflaRx N.V., and consider following IFRX for alerts when major investors trade the stock.
InflaRx N.V. is classified in the Healthcare sector. On ROE, it currently shows -19.16% versus a sector average near 13.26%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing IFRX with unrelated industries.